-
Affiliation
-
School of Medicine, Collaborative Research Resources (Laboratory of Cell and Tissue Biology) (Shinanomachi)
-
Position
-
Instructor
-
External Links
-
-
Hiroko Nishida
|
|
|
Research Areas 【 Display / hide 】
-
Life Science / Hematology and medical oncology
-
Life Science / Tumor diagnostics and therapeutics
Research Themes 【 Display / hide 】
-
難治性多発性骨髄腫のCD26の発現誘導を制御するHDACアイソフォームの役割,
2019.04-Present -
難治性多発性骨髄腫のヒト化抗CD26モノクローナル抗体を用いた分子標的療法の開発,
2016.04-2019.03 -
難治性溶骨性骨転移のヒト化抗CD26モノクローナル抗体を用いた分子標的療法の開発,
2013.04-2016.03
Books 【 Display / hide 】
-
目でみるトレーニング第2集
西田浩子, 医学書院, 2013.06
Scope: 207-208
-
medicina
Nishida Hiroko, 医学書院, 2011.09
Scope: 1655-1659, Vol.48, No.9
-
medicina
Nishida Hiroko, 医学書院, 2010.07
Scope: 1302-1305, Vol.47, No.7
-
目でみるトレーニング第2集
西田 浩子, 2013.06
Scope: 207-208
-
EBM 血液疾患の治療 2005-2006
西田 浩子, 村田 満, 中外医学社, 2004.09
Scope: 694-700
Papers 【 Display / hide 】
-
HDAC inhibition induces CD26 expression on multiple myeloma cells via the c-Myc/Sp1-mediated promoter activation
Hiroko Nishida, Reiko Suzuki, Kiyora Nakajima, Mutsumi Hayashi; Chikao Morimoto, Taketo Yamada
Cancer Research Communications (AACR) 4 ( 2 ) 349 - 364 2024.01
Research paper (scientific journal), Joint Work, Lead author, Accepted
-
Rapid progress in immunotherapies for multiple myeloma: an updated comprehensive review
Hiroko Nishida
Cancers (Basal) 13 ( 11 ) 2712 2021.05
Research paper (scientific journal), Single Work, Accepted
-
Monoclonal antibody therapies in multiple myeloma: a challenge to develop novel targets.
Hiroko Nishida, Taketo Yamada
Journal of Oncology 6084012 1 - 10 2019.11
Research paper (scientific journal), Accepted
-
Novel antibody-drug conjugate with anti-CD26 humanized monoclonal antibody and transcription factor IIH (TFIIH) inhibitor, triptolide, inhibits tumor growth via impairing RNA synthesis.
Mutsumi Hayashi, Hiroko Madokoro, Koji Yamada, Hiroko Nishida, Chikao Morimoto, Michiie Sakamoto, Hiroshi Yanagawa, Taketo Yamada
Cancers (Basal) 11 ( 8 ) 1138 2019.08
Research paper (scientific journal), Accepted
-
CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma.
Hiroko Nishida, Mutsumi Hayashi, Michiie Sakamoto, Chikao Morimoto, Taketo Yamada
Blood Cancer Journal 8 ( 99 ) 1 - 17 2018.10
Research paper (scientific journal), Joint Work, Accepted
Reviews, Commentaries, etc. 【 Display / hide 】
-
Bone-Targeted Agents in Multiple Myeloma
Hiroko Nishida
Hematology Reports 10 12 - 16 2018.03
Article, review, commentary, editorial, etc. (scientific journal), Single Work
-
Bone Targeted Therapy in Multiple Myeloma
Hiroko Nishida
International Journal of Hematological Disorders 3 ( 1 ) 3 - 6 2017.03
Article, review, commentary, editorial, etc. (scientific journal), Single Work
Presentations 【 Display / hide 】
-
HDAC inhibition involves CD26 expression on multiple myeloma cells via the c-Myc/Sp1-mediated promoter activation and overcomes therapeutic resistance by humanized antibody
Hiroko Nishida, Reiko Suzuki, Kiyora Nakajima, Michiie Sakamoto
EHA 2023 Hybrid Congress (Frankfurt, Germany) ,
2023.06,Poster presentation, European Hematology Association
-
HDAC inhibition involves CD26 induction on multiple myeloma cells via the c-Myc/Sp1-mediated promoter activation and overcomes therapeutic resistance by humanized antibody.
Hiroko Nishida, Reiko Suzuki, Kiyora Nakajima, Mutusmi Hayashi, Michiie Sakamoto
64th ASH Annual Meeting & Exposition (New Orleans, LA, USA) ,
2022.12,Poster presentation, American Society of Hematology
-
HDAC inhibition involves CD26 induction in myeloma cells via the Sp1-mediated promoter activation.
Hiroko Nishida, Reiko Suzuki, Mutsumi Hayashi, Michiie Sakamoto
84th Japanese Society of Hematology Annual Meeting (Fukuoka) ,
2022.10,Oral presentation (general), Japanese Society of Hematology
-
Isoform-selective HDAC inhibition up-regulates CD26 expression on multiple myeloma cells and augments cytotoxic efficacy by humanized monoclonal antibody.
Hiroko Nishida, Mari Fujiwara, Mutsumi Hayashi, Michiie Sakamoto
AACR Annual Meeting (New Orleans, LA, USA) ,
2022.04,Poster presentation, American Association for Cancer Research
-
Up-regulation of CD26 on myeloma cells by HDAC inhibition enhances the efficacy of humanized antibody
Hiroko Nishida, Mari Fujiwara, Chikao Morimoto, Michiie Sakamoto
83rd Japanese Society of Hematology, Annual Meeting (Sendai) ,
2021.09,Oral presentation (general), Japanese Society of Hematology
Research Projects of Competitive Funds, etc. 【 Display / hide 】
-
難治性多発性骨髄腫のCD26の発現誘導を制御するHDACアイソフォームの役割
2020.04-2025.03文部科学省, Grant-in-Aid for Scientific Research, HIROKO NISHIDA, 基盤研究(C), Research grant, Principal investigator
-
核内移行するヒト化抗CD26抗体によるスーパーエンハンサー標的抗がん療法の開発
2019.04-2022.03文部科学省, Grant-in-Aid for Scientific Research, 基盤研究(B), Research grant, Coinvestigator(s)
-
病理検体を用いたCHIPseq法の開発と疾患特異的スーパーエンハンサーの同定
2019.04-2021.03日本学術振興会, 挑戦的研究, Research grant, Coinvestigator(s)
-
難治性多発性骨髄腫のヒト化抗CD26モノクローナル抗体を用いた分子標的療法の開発
2016.04-2020.03文部科学省, Grant-in-Aid for Scientific Research, HIROKO NISHIDA, 基盤研究(C), Research grant, Principal investigator
-
ヒト化抗体とCD26の核内移行によるRNAポリメラーゼII標的抗がん療法の開発
2016.04-2019.03Grant-in-Aid for Scientific Research, 基盤研究(B), Research grant, Coinvestigator(s)
Awards 【 Display / hide 】
-
文部科学省戦略的研究基盤形成支援事業’疾患モデル動物を用いた病態解明と革新的治療法の開発‘プロジェクト若手研究者研究助成
Nishida Hiroko, 2009.09, 文部科学省戦略的基礎研究推進事業, 急性リンパ性白血病における癌幹細胞の同定と解析、及び臨床における有用性の評価
Type of Award： Keio commendation etc.
-
Keio University Resarch Grants for Life Science and Medicine
Nishida Hiroko, 2008.05, 慶應義塾医学振興基金, Identification and analysis of cancer stem cells in acute lymphoblastic leukemia and its clinical evaluation.
Type of Award： Keio commendation etc.
Memberships in Academic Societies 【 Display / hide 】
-
日本血液学会
-
日本内科学会
-
American Society of Hematology
-
日本臨床腫瘍学会
-
日本造血細胞移植学会